Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Investigating the safety and efficacy of re-treating CLL patients with venetoclax-based regimens

Paula Cramer • 10 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Obinutuzumab Venetoclax
CLL14

In this video, Paula Cramer, MD, University of Cologne, Cologne, Germany, shares some results from a study evaluating the safety and efficacy of re-treating chronic lymphocytic leukemia (CLL) patients with venetoclax-based regimens following relapse. Dr Cramer first explains the rationale behind this study, and then discusses the patient population enrolled. Following this, Dr Cramer highlights the results obtained, which suggest that re-treatment with venetoclax-based regimens appears to be safe and efficacious, with no increase in adverse events (AEs). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Paula Cramer

1:42
The role of allo transplantation in CLL
Paula Cramer • 8 Oct 2023
1:29
Future research into MRD-guided treatment of CLL
Paula Cramer • 8 Oct 2023
3:28
Update on the CLL2-BAAG trial
Paula Cramer • 8 Oct 2023
1:22
The future of CLL treatment and more personalized approaches
Paula Cramer • 10 Jun 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals